UNSPSC 51334314: Flupentixol hydrochloride

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C23H25F3N2OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96L0Z069N1, chemically known as 1-piperazineethanol, 4-(3-(2-(trifluoromethyl)-9h-thioxanthen-9-ylidene)propyl)-, (e)- but more generally known as flupentixol dihydrochloride, which bears US NIH Compound Identifier 5281878.

European Medicines Agency schedules Flupentixol dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02229MIG. Most nations, for tariff and trade purposes, schedule flupentixol hydrochloride under HS 29349990. SMILES: C1CCC2C(C1)/C(=C/CCN3CCN(CC3)CCO)/C4CC(CCC4S2)C(F)(F)F.CL.CL.

UNSPSC 51334314 Flupentixol hydrochloride is a Commodity code representing a specific antipsychotic pharmaceutical product. However, the recent state and local opportunities tagged under this code show limited direct procurement of flupentixol itself; instead, the tagged solicitations reflect broader pharmaceutical procurement patterns across state and local health systems, including generic multi-source drugs, over-the-counter products, and emergency-response pharmaceuticals like naloxone. State and local governments acquire pharmaceutical products through a mix of direct purchases, cooperative purchasing agreements, and RFIs that gather vendor capacity before formal solicitation. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and participating jurisdictions). Pharmaceutical procurement is frequently coordinated through established wholesaler networks and requires vendors to hold current Good Manufacturing Practices certification, comply with the Drug Supply Chain Security Act, and meet FDA requirements.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities through three authorized wholesalers, with contract awards effective July 1, 2026 and pricing weighted 75 percent on competitiveness. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, under a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs, seeking information about vendors' experience with direct contracting for self-insured employers and capacity for outcomes-based agreements before issuing a formal RFP. Cooperative purchasing vehicles dominate the landscape, with MMCAP requiring vendors to maintain relationships with at least two of three authorized wholesalers and imposing performance penalties of $200 to $1,500 per violation.